BIOHK2021

香港國際生物科技展





THE DEFINITIVE BIOTECH CONVENTION IN ASIA 亞洲最權威的生物科技大會

BIOHK2021 is the Hong Kong first international biotechnology convention organized to introduce novel state-of-the-art biotech innovations from around the globe, with the purpose of providing an extensive platform to allow pioneers of the biotech industry to convene. The target includes policy maker, industry, academic, research, investment and end-use.

The event includes Exhibition, Conference and One2One business matching. It provides an ideal opportunity to promote your business or organization to the investors and industry leaders from all over the world. Being Asia's World city and a member of Guangdong-Hong Kong-Macau Greater Bay Area, Hong Kong is a perfect place to host this global mega biotech event, to provide the global biotech stakeholders a permanent convention to meet every year in Asia.

BIOHK2021香港國際生物科技展是香港 首個國際生物科技展,是向全球推廣您產品 的絕佳機會,對象包括官、產、學、研、投、用。

BIOHK2021包含展覽會、學術演講及專案交流會、一對一商機配對,匯聚全球最權威生物科技、製藥及金融界行業領袖,是與業界人士建立聯繫交流的理想平臺。作為亞洲的世界城市和粵港澳大灣區最國際化的城市,香港是舉辦全球大型生物技術活動的最佳地點。讓我們共同努力,把BIOHK2021打造成為亞洲最主要的生物科技盛事。



HONG KONG

INTRODUCTION

Hong Kong, often considered the gateway to China due to its unique status as a special administrative region, offers a rich source of opportunities for overseas investors looking to capitalize on the continued growth of the Greater Bay Area – a scheme initiated by the Chinese government to link Hong Kong and 10 other cities along the Pearl River Estuary and form an international technology and innovation centre rivalling that of Silicon Valley.

With its strong exposure and international integration, Hong Kong has become the go-to stepping stone for Chinese companies looking to expand abroad. New listing rules adopted by the Hong Kong Exchanges and Clearing Limited (HKEX) chapter 18A allows pre-revenue biotech companies to be listed on the exchange. A first in Asia, it ensures more capital can flow freely towards a sector that's been largely deprived in the region until recently. As of 30th June 2021, there are over 50 healthcare and biotech companies had submitted IPO

applications, including 19 pre-revenue biotech companies pursuing a Chapter 18A listing and one international issuer. Since its launch in December 2019, the Hang Seng Hong Kong-Listed Biotech Index (HSHKBIO) has generated a return of 55%, or an annualised return of 40%, which is a clear validation of the maturing sector. As such, Hong Kong has the potential to be at the epicenter of Asia's biotech revolution and it is our hope that BIOHK2021 will help set this in motion.

As a city with a rich history in industrial development and innovation, and one that is frequently coined "Asia's World City", there is no better place to bring biotech companies from East and West together other than here at BIOHK2021. The first of its kind in Hong Kong, the convention represents a new chapter both for the local biotech industry and the city itself. Take charge and seize the many opportunities available and engage with global industry leaders at BIOHK2021!

BIOHK2021

簡介

粵港澳大灣區(GBA)是由中國政府發起,將香港 和珠江口其他10個城市連接,形成一個與美國矽谷 相媲美的國際科創中心,旨在令海外投資者憑借粵港 澳大灣區的持續經濟增長,獲得豐富的發展機會。依 托強大的知名度和國際一體化優勢,香港已成為中國 企業尋求海外拓展的的跳板。香港交易所採用新的上 市規則,允許生物科技公司證明其特點,即使不符合 盈利測試或收益測試的前提下,亦可獲准根據第18A 章上市。作為亞洲第一個實行該政策的城市,這項政 策打破了資本流通壁壘,確保了更多的資本能夠自由 流向本地區。截至2021年6月30日,已有超過50家 醫療保健和生物科技公司提交了首次公開募股的申請、 其中包括19家未有盈利的生物科技公司和1家國際發 行人。自2019年12月推出以來,HSHKBIO*已產 生55%的回報,或40%的年度回報,這是對生物科 技行業的肯定。因此,香港有巨大潛力成為亞洲生物 科技革命的中心, 我們希望BIOHK2021將成為推動 這一進程的里程碑。

香港作為一個具有豐富工業發展和創新歷史,同時又被定義為"亞洲國際都會"的城市,BIOHK2021是將東西方生物科技公司聚集在一起的最好機會,為本地生物科技產業翻開新的篇章。抓住機遇,與全球業界領袖在BIOHK2021攜手合作!

*HSHKBIO: 恒生香港上市生物科技指数



EIDOSCOPE

無限的可能 ITE POSSIBILI 科技萬花筒, **Z**

萬花筒 KALEIDOSCOPE

A popular children's toy that when rotated creates a continually changing symmetrical pattern from the loose bits of glass inside the tube and the mirrors set towards one another; the kaleidoscope is symbolic of what we hope BIOHK2021 brings to biotech in the region; a continually shifting scene with **infinite possibilities** and **no limits** to what can happen.

Biotech's future is in Asia and it is our mission to make Hong Kong the centre of it.

一種兒時流行的玩具,旋轉時會從筒內的玻璃碎 片和鏡子向彼此擺放的位置連續產生不斷變化的 對稱圖案;萬花筒象徵我們期望BIOHK2021為 香港的生物科技帶來干變萬化的可能。

生物技術的未來就在亞洲,我們的使命是使香港成為未來亞洲生物科技創新中心。

CONVENTION CONSISTS OF

會議內容

EXHIBITION


展覽會

CONFERENCE & PITCH SESSIONS

學術演講及專案交流會

ONE2ONE BUSINESS MATCHING

一對一商機配對



PITCH AND CONNECT

演示與聯繫

The BIOHK2021 exhibition is a platform for early stage spin-outs and established firms in all areas including healthcare to pitch their visions backed by the strength of customized branded exhibits. It is a perfect opportunity to make meaningful in-person business connections with senior level management and investors. Filled with the latest trends, technology, companies, and breakthrough ideas in biotechnology and pharmaceutical, this exhibition must not be missed!

- Meet and connect with prospective customers or strengthen your bond with existing customers
- Learn about new developments in your industry
- Meet new companies that can help your business
- Strengthen (or establish) your brand
- Learn about your competitors
- Expand your sales lead database
- Speak directly to your target market
- Optimize your sales and lead generation strategy

展覽會旨在為來自世界各地的參展商提供一個展示其產品和創新的平臺,並藉此機會瞭解全球生物科技行業及相關領域高級管理者和投資者所關注的熱點。展覽會囊括了生物科技和醫藥領域最新趨勢、技術、和突破性的創新思維。本次展覽會絕對不可錯失!

- 與潛在客戶會面及建立聯繫,並加強 與現有客戶的聯繫
- 瞭解行業的新發展
- 遇見對您的業務增長有幫助的新公司
- 在展覽期間與客戶簽署訂單
- 進一步加強(或建立)品牌
- 向競爭對手學習
- 更快速地擴展行銷資料庫
- 直接與目標市場聯繫
- 優化銷售和搜集潛在客戶的策略



學術演講及專案交流會

SHARE AND INSPIRE

分享與啟發

BIOHK2021 is a platform for investors, entrepreneurs, leaders and international scientists to have in-depth discussions and share on latest regional and international researches as well as findings. You can exchange ideas, professional experience across a wide range of topics in different sessions, panel discussions and podium talks. There is no language barrier as the conference will provide simultaneous interpretation supporting all English, Cantonese and Mandarin.

We expect over 7,000 visitors and 150 guest speakers to attend the conference and keynote lectures. There will also be 300 companies and organizations participating in the pitch sessions to present their ideas.

A portion of the event will open to the public. Visitors can participate in different popular science lectures to understand the development trend of the biotechnology industry and its innovative technologies.

BIOHK2021為深入討論研究成果和未來發展趨勢提供了平臺。在兩文三語的互動會議、小組討論和講臺演講中,來自不同領域的思想家、科學家、投資者和創業人士將匯聚一堂,就廣泛的議題,分別對研究成果、專業發展和創新思維進行討論與經驗分享。

我們預計將超過7,000名與會者,150多 名專題演講嘉賓,300多間企業、機構及 學術團體參與,展示其研究成果和產品, 在廣闊的市場中尋找長期合作夥伴。

展覽將在指定日期向公眾開放。參觀人士可以參與不同的科普講座,瞭解和認識生物科技行業的發展趨勢及其創新技術。參展商可藉此機會讓產品直接面向大眾,除提升品牌知名度外,亦可測試產品在市場上的競爭力,從而了解並提升產品競爭優勢!

Scan NOW and Join US



oio-hk.com

The conference is partly funded by Innovation and Technology Fund (ITF). 會議部分由總新技術基金 (ITF) 資助。

商機配對 11

PROMOTE AND ESTABLISH

宣傳和建立

Bringing the world together to navigate and capitalize on the opportunities in Hong Kong as a burgeoning biotech hub, the One2One Business Matching intends to aid attendees in identifying and connecting prospective partners in the form of investors, analysts and partnering companies for future collaborations. Align your goals and maximize your returns with other parties in the future of biotech.

- Networking opportunity with the industry practitioners, academicians, delegates from reputed biopharma firms and educational institutions
- Spot your prospective partners investors, analysts, partnering companies to fuel your next big breakthrough
- Form valuable partnerships with leading biotech firms
- Meet and greet with high-level executives
- Build promising partnerships in a wide spectrum of marketplaces

「一對一商機配對」協助參展商以投資者、 分析師或合作夥伴公司的角色,與潛在的 合作夥伴進行面談;通過識別和約見合作 夥伴,為您的公司發展奠定基礎,使之成 為業界「值得關注的公司」,吸引更多公 司進行投資,獲得更大的回報。

- 與業界從業人員、學者、知名生物製藥公司和教育機構建立聯繫的機會
- 定位潛在合作夥伴──投資者、分析師、合夥人
- 與領先的生物技術公司建立寶貴的夥伴關係
- 與企業高層交流
- 在廣泛的市場中尋找和建立有希望的 夥伴關係
- 投資人向技術發明者提供商業建議的 機會
- ▼探索香港與大灣區成為您下一個創業基地

ABOUT 關於 HONG港 TONG TONG TONG TONG TONG

CONVENTION CAPITAL

會議首選之都

"One Country, Two Systems"

World class infrastructure

Strategically positioned as a connector between East and West

Biliteracy and trilingualism (Cantonese-Mandarin-English)

International innovation and technology hub in Greater Bay Area

兩文三語

作為東西方聯繫的重要角色

世界一流的設施

一國兩制」

大灣區國際科技創新中心

WHY BIOTECH CONVEN-TION IN HONG KONG?

Hong Kong is at the centre of the converging goals and visions between key regional and global industries, finance, academic, research and innovation sectors; rising to an excellent opportunity to capitalize on Hong Kong's position as a globally strategic hub for biotech.

- The Chinese President Xi Jinping directed state to develop Hong Kong into an international innovation and technology hub
- The Innovation and Technology Fund has funded over 1.3 billion on more than 640 biotech projects and aims to attract more world-class scientific research institutions & technology enterprises
- Hong Kong Exchanges and Clearing Limited's biggest listing reform in 25 years sees
 the establishment of a new chapter 18A, allowing pre revenue and pre profit biotech
 companies to be listed a first in Asia and a show of the HKEX's commitment to
 developing a biotech ecosystem
- About 1,300 high technology companies and incubates are currently resided in the Hong Kong Science and Technology Parks (HKSTP) and Cyberport
- There are currently over 440 btiotech-related companies in the city
- Hong Kong is the preferred destination for multinationals wanting to set up regional headquarters and offices
- Hong Kong's start-up scene has experienced phenomenal growth in recent years
- Several incubators and accelerators offer comprehensive incubation programs to start-ups for promoting local biotech scene
- Extensive experience in commercializing innovative technology for industrial application through branding & marketing

為什麼在香港 舉辦生物科技展?

- 習近平主席已指示,支持香港成為國際創新科 技中心
- 交易所已允許前期無收益的生物科技公司能夠 在創業板上市,這是股票市場歷史的一個里程 碑
- 創新及科技基金已資助超過640個生物科技專案,撥款額高達13億元,旨在吸引更多世界一流的科研機構和科技企業
- 香港科學園和數碼港已有約1300家高科技公司和孵化器公司入駐
- 目前,全港有超過440家生物科技相關的公司
- 香港是跨國公司設立辦事處和區域總部的首選地
- 近年來,香港的初創企業經歷了驚人的增長
- 多個孵化器和加速器為初創企業提供全面的孵化計畫,以推廣當地的生物科技領域
- 在工業應用和品牌行銷的創新技術商業化方面 具有豐富的經驗



HONG 香港可 KONG 提供 CAN OFFER

WORLD-CLASS R&D CAPABILITY ACTIVE ENTREPRENEURIAL ECOSYSTEM GATEWAY TO THE VAST CHINA MARKET SOUND REGULATORY REGIME TESTING & AUTHENTICATION SERVICES

IP PROTECTION

EXCELLENT FUND RAISING PLATFORMREPUTABLE QUALITY CONTROL & ASSURANCE

FREE & OPEN ECONOMY

STRONG INTERNATIONAL INVESTOR BASE

TRANSPARENT VETTING PROCESS

BUSINESS FRIENDLY TAX RATES

ONE OF THREE VENTURE CAPITAL CENTERS

INNOVATION & TECHNOLOGY FUND

ABUNDANT LIQUIDITY

ESTABLISHED FINANCIAL & LEGAL SYSTEMS

通往廣闊中國市場的大門 透明的審查程序 健全的金融和法律體系 自由開放的經濟 信譽良好的質控保證 卓越的籌款平臺 世界級的研發能力 健全的監管制度 活躍的創業生態系統 世界三大投資金融中心之一 有利的商業稅收 。強大的國際投資者基礎

FUTURE OF BIOTECH IN THE REGION 生物科技在區域內的未來發展

Out of China's 199 science parks, 111 are biotechnology parks, with 93 concentrated In the Greater Bay Area.

Under the influence of the epidemic, China's medical industry has taken off. The amount of private equity financing, IPO and M&A transactions in the whole year broke through 45 billion US dollars, with the efforts of entrepreneurs, investors and investment banks.

China's DNA sequencing market is expected to grow from 7.2 billion yuan last year to 18.3 billion yuan by 2022, studies show that it is growing much faster than the overall global market because of the rising income and growing investment in health care infrastructure.

Hong Kong Stock Exchange's biggest listing reform in 25 years (effective from April 30th 2018) sees the establishment of a new biotech chapter allowing biotech companies that are pre revenue or that are not profitable to be listed – a show of the HKEX's commitment to developing a biotech ecosystem.


Guangdong - Hong Kong - Macao Greater Bay Area (GBA) was established in 2017, promoting joint and coordinated regional economic development. 在中國199個科學園區中,有111個是生物 科技園區,其中有93個集中在粵港澳大灣 區。

中國醫療行業在疫情的影響下反而进發出了騰飛態勢——全年私募融資、IPO和並購交易金額突破450億美元,這是來自創業家、投資者以及投行的付出和努力。

研究顯示,到2022年中國的DNA測序市 場將從去年的72億元增長到183億元人民 幣。由於收入的增加和對醫療基礎設施投 資的增加,增長速度將領先全球市場。

香港證券交易所25年來最大規模的上市改革(自2018年4月30日起生效)開啟了生物科技改革的新篇章,允許未有盈利或收益的生物科技公司在證明其具備的特點後,亦可獲准上市——成為了世界第二大生物科技上市平臺。

粵港澳大灣區(GBA)成立於2017年,旨 在促進區域經濟合作協調發展。



Hong Kong Tour

Dubbed the "Pearl of the Orient", Hong Kong is a uniquely colourful, chaotic and glamorous city with a rich cultural and historical past. Admire the dazzling neon lights of Victoria Harbour on board the iconic Star Ferry and relive 19th century Hong Kong on board the historic Peak Tram. Learn about life in Hong Kong, its culture, rich history and people by joining the tour!

香港觀光

香港被譽為"東方之珠",是一個多姿多彩、多元化有魅力的城市,擁有豐富的歷史文化。乘坐香港的標誌性交通工 具——天星小輪,欣賞夜晚絢爛多彩的維多利亞港霓虹燈,重溫19世紀香港的山頂纜車。觀光活動受到旅遊局及政府 支持,加入我們,驗解香港的生活、悠久的歷史、豐富的文化和香港的居民。

Greater Bay Area Tour

Of China's 199 science parks, 111 are biotechnology-related, with 93 concentrated in the Greater Bay Area. Get an in depth look into this high-tech research and manufacturing epicentre by joining our Greater Bay Area tour. Specially organized for BIOHK2021 attendees, there are several Greater-Bay's science parks and attractions will be arranged for them to visit.

粤港澳大灣區行程

在中國199個科學園區中,有111個是生物科技園區,其中有93個集中在粵港澳大灣區,通過加入我們的粵港澳大灣區之旅,深入瞭解這個高科技研究和製造業中心。我們為BIOHK2021的參加者特別安排的一日遊行程,首先會穿越世界上最長的跨海大橋——港珠澳大橋,然後前往我們從粵港澳大灣區無數的科學園和景點中精心挑選的幾個地方進行參觀。

Award Ceremony

The development of China's biotechnology is mature, in addition to national support and cultivation, it is more important that a group of biotechnology companies, practitioners, scholars, who achieve it through years of hard work and effort. Through BIOHK2021, we hope to commend a lifetime contribution to biotechnology researchers and professionals, send them the highest respect!

頒獎禮

在亞洲生物科技發展過程中,除了國家支持及培育,更重要的是眾多生物科技公司、從業人員、學者等等多年的努力才可達成。通過BIOHK2021, 我們希望借此表彰畢生為生物科技研究而奮鬥的專業人士,感謝他們的貢獻。若您心目中有合適人選, 歡迎提名參與!

Public Day

In order to enhance the public's understanding of biotechnology, we will arrange one of the days as an open day for the public. Students, parents, organizations and publics are welcome to participate in the event. Various types of activities, interactive games, and public seminars will be arranged on the day in order to build the public interest and awareness of biotechnology.

公眾開放日

為了加強公眾對生物科技的認識,我們選定部分日子為公眾開放日,歡迎學生、家長、團體及其他公眾人士來參與此次 活動。當天將安排各類型活動,互動遊戲及公眾講座等等,從而建立大眾對生物科技的興趣和認知。

ABOUT 關於主辦單位

ORGANISERS



Hong Kong Biotechnology Organization (HKBIO) established in 2010 by reputable industry and esteemed academic representatives, is a non-profit organization which continuously strives to promote Hong Kong as the biotech hub of Asia. HKBIO has organized and sponsored several successful events in the past that highlighted the substantial potential of Hong Kong's biotechnology sector.

香港生物科技協會由著名業界人士及受人尊敬的學術代表於2010 年創立,是一個非營利性機構,致力於持續推動香港成為亞洲的 生物科技中心。香港生物科技協會過去曾多次成功舉辦及贊助多 項活動,突顯香港生物科技的巨大潛力。



The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members.

百華協會是由全球生命科技和醫藥健康產業領域中的商業領袖組成的非營利性會員組織。百華協會致力於在中美亞太地區促進生命科技和醫療健康產業的成長壯大,不斷醞釀創造商機,提供培養業界領導人才,協助會員交流分享資訊和經驗。



Ausvic Capital is a global biotech, artificial intelligence (Al) and cloud computing-focused investment group founded by leading investors in 2018. The team has extensive experience in venture capital investing and business management, with an impressive track record behind their name. Leveraging on its extensive network around the world, Ausvic focuses on the most novel life science and Al-related companies and technologies in the United States, Europe, and China.

盈信泰資本成立於2018年,是由擁有眾多股權投資背景的專業人士發起建立的前沿科技投資管理機構。基金重點投資領域包括生物科技,AI+雲服務,雲計算。早期基金主要投資A輪,後期基金主要投資Pre-IPO。主要創始人擁有豐富的高科技領域風險投資及企業管理經驗,並創造了驕人的業績。

SPECIAL THANKS TO... 特別鳴謝 (in alphabetical order space 按文字母期)則

It's never too late to join and become our partner!

立即加入並成為我們的合作夥伴吧!

Co-organisers

協辦單位









Diamond Sponsors 鑽石贊助









* EE'S PHARM. 李 氏 大 薬 扇

Gold Sponsors 黃金贊助



Special Supporting Organisations















Global Partners 全球合作夥伴



























Supporting **Organisations**





















































































































Media **Partners** 媒體合作夥伴







D大田-田田







Official Carrier





Undertaken by 承辦方

BIOHK Ltd.

BIOHK2021香港國際生物科技展





Biotechnology has witnessed a paradigm shift every two decades, starting with the US in the 1980s and Europe in the 2000s. As we enter the **2020's**, **Asia** is emerging as the world's next **biotech powerhouse**.

從20世紀80年代的美國和21世紀的歐洲開始,生物技術每二十年就發生一次範式轉變,

隨著我們進入2020年,亞洲正在成為世界上一個強大的生物科技中心。

Being Asia's World City and the most international city in the Guangdong-Hong Kong-Macau Greater Bay Area, **Hong Kong** is a perfect location to host this BIOHK2021 global mega biotech event, so the global biotech stakeholders have a permanent convention to meet every year in Asia. 作為亞洲的世界城市和粵港澳大灣區最國際化的城市,香港是舉辦全球大型生物技術活動的最佳地點。讓我們共同努力,把BIOHK2021香港國際生物科技展打造成為亞洲主要的生物科技活動。

Scan to register! 掃描二維碼立刻參會



www.bio-hk.com

BIOHK2021 convention comprises 香港國際生物科技展包括

EXHIBITION 展覽會

> Pitch and Connect 拓展市場與建立關系網

CONFERENCE & PITCH SESSIONS 學術演講及專案交流會

> Share and Inspire 分享與啟發

ONE2ONE BUSINESS MATCHING 一對一商機配對

> Promote and Establish 促進與建立合作

Please scan the QR code and visit our website for more details 更多精彩内容請您掃描二維碼瀏覽網站

Follow us 關注我們
















地址 Address

香港新界香港科學園科技大道西9號 生物科技中心一座601-605室 Units 601-605, 6/F, Biotech Centre One, 9 Science Park West Avenue, Hong Kong Science Park, N.T., HK

電郵 E-mail: info@bio-hk.com 電話 Phone: +852 2799 7688

The conference is partly funded by Innovation and Technology Fund (ITF). 會議部分由創新技術基金 (ITF) 資助。

製鋼助労組制的技術を全(IFT)。 Any opinions, findings, conclusions or recommendations our present in this netheralizement (or by membors of the project team) do not reflect Any opinions, findings, conclusions or recommendations our present in the netheralizement of the control of Technology Commission or the Vetting Committee of the General Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Programme of the Innovation and Technology Funds (Project Support Project Support Proj